 dideoxyinosin children symptomat human immunodefici viru infect background ddl dideoxynucleosid potent activ vitro human immunodefici viru hiv initi clinic trial adult ddl evid antiretrovir activ littl hematolog toxic method phase i-ii studi children symptomat cdc class hiv infect children median age year zidovudin median age year ddl divid dose mg squar meter body-surfac area day week patient complet week ddl progress diseas toxic result oral administr ddl bioavail patient pancreat children receiv ddl dose median cell count patient pair count liter cubic millimet base line liter cubic millimet week cell count liter cubic millimet base line like respect median level antigen patient detect level entri pg millilit base line pg millilit week plasma concentr ddl degre declin antigen degre improv IQ score improv clinic immunolog measur untreat patient zidovudin conclus dideoxyinosin promis antiretrovir activ hiv-infect children correl clinic respons plasma concentr ddl bioavail import consider use ddl hiv infect individu pharmacokinet monitor dose adjust import optim activ